Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) Initiates New Phase 1 Study in R/R Multiple Myeloma

March 7, 2018 8:03 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in a phase 1 clinical trial evaluating the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News Management Comments

Next Articles